Originally published on Best Stocks Category: best stocks to buy now Source: Getty ImagesThe stock market can be an intimidating place for the uninitiated. To help you get started, we’ve outlined some of the best stocks to buy now and how you can invest in them. Keep reading to discover more. If you’re interested in investing but need help knowing where to start, you’re not alone. Many people shy away from the stock market because they assume it’s only for wealthy business moguls or trust fund babies with too much money and not enough sense to spend it on something useful like a new car or tropical vacation. Fortunately, nothing could be further from the truth. Investing in stocks is one of the most straightforward ways for ordinary individuals to build wealth over time while also having the opportunity to increase their capital substantially over time through reinvestment of dividends and other profits from their initial investments.DocuSign (NASDAQ: DOCU)Source: Getty ImagesDocuSign is a cloud-based document management company specializing in simplifying and expediting the contract review process between businesses and their clients. That includes everything from real estate and construction agreements to service contracts and customer service agreements. In addition to facilitating contract review, the company provides companies with legally binding signatures on those contracts, allowing for quick and secure settlement on all agreements between parties. As of September 30, 2018, DocuSign had approximately 26 million users across all industries and 16 million active users. It provides its services through a SaaS (Software as a Service) model, providing the software for free and billing customers based on their usage. Why This Stock Could Be a Great Investment: DocuSign is one of the best stocks to buy now because it’s a leader in an industry that’s expected to see rapid growth. The global e-signature market, which includes services like DocuSign, is projected to reach $50 billion by 2021, a 10-year compounded annual growth rate of nearly 13%. This growth is expected to be driven by the desire of companies to simplify and expedite the contract review process, particularly given the regulatory environment is becoming increasingly stringent around the world. As a result, the e-signature market is expected to increase, creating a solid tailwind for companies like DocuSign. Finally, DocuSign is also a reasonably low-risk stock, given its dominance in the industry, high recurring revenue, and strong balance sheet. That should help it to remain profitable and cash-flow positive even if the overall economy slows down or there is a downturn in business investment.Siga Technologies (NASDAQ: SIGA)Siga Technologies is a biopharmaceutical company specializing in developing infectious disease vaccines. Its flagship product is Immunotherapy for Hepatitis B Virus, or IHB, designed to treat hepatitis B infections. The company also has other products in development for dengue, gonorrhea, and other serious infectious diseases. As of September 30, 2018, the company had $135.4 million in cash, cash equivalents, and short-term investments. Its Immunotherapy for Hepatitis B Virus was approved in Mexico in December 2017 and in the United States in February 2018. Why This Stock Could Be a Great Investment: Siga Technologies is one of the best stocks to buy now because it’s expected to see strong growth in the coming years. According to the World Health Organization, an estimated 257 million people worldwide were infected with hepatitis B in 2016. Many of these people, however, are unaware that they are infected and, therefore, unlikely to receive treatment. As a result, the need for better treatment and preventative measures for hepatitis B is immense and could create a substantial opportunity for Siga. That is especially true given that the cure for hepatitis B currently requires daily injections for six months or longer, which may be too demanding for many patients to adhere to. In addition, Siga also has other products in development that could create substantial value for investors in the future.T2 Biosystems Inc. (NASDAQ: TTOO)T2 Biosystems Inc. is a molecular diagnostics company that develops non-invasive blood tests used in clinical laboratories to identify infectious diseases, help prevent bacterial transmission, and identify the risk of sepsis. Its products are mainly used in hospitals, where they can reduce the risk of infections and sepsis in patients. As of September 30, 2018, the company had $38.7 million in cash and cash equivalents. The company also has a strong balance sheet, with $74.3 million in total assets and $46.8 million in total liabilities. Why This Stock Could Be a Great Investment: T2 Biosystems Inc. is one of the best stocks to buy now because it’s expected to see strong growth in the coming years. According to the Centers for Disease Control and Prevention, hospital-acquired infections account for 99% of all sepsis cases and are responsible for thousands of deaths yearly. As a result, there is a substantial opportunity for T2’s products to help hospitals reduce the risk of bacterial transmission and the spread of infection. In addition, the company has other products in development and a proven track record, with several of its current products generating more than $10 million in sales. This history of success should help the company grow its revenue and cash flow over the long term.Inovio Pharmaceuticals (NASDAQ: INO)Fonte: Getty ImagesInovio Pharmaceuticals is a biopharmaceutical company that is focused on the discovery and development of DNA-based immunotherapies. The company works in the field of immuno-oncology, utilizing its technology to develop vaccines designed to treat and prevent cancers. Its lead product is VGX-3100, an investigational vaccine designed to treat HPV-associated diseases, including cervical cancer, other cancers, and genital warts. As of September 30, 2018, the company had $245.2 million in cash and cash equivalents. In addition, it has a strong balance sheet, with $265.3 million in total assets and $10.6 million in total liabilities. Why This Stock Could Be a Great Investment: Inovio Pharmaceuticals is one of the best stocks to buy now because it’s expected to see strong growth in the coming years. According to the World Health Organization, more than 500,000 people die yearly from HPV-associated cancers. That represents an enormous unmet medical need, which Inovio Pharmaceuticals hopes to address with its lead vaccine. In addition, the company is also developing vaccines to treat other infectious diseases, including Lyme disease, dengue fever, and the flu. This diversified product pipeline should help it maintain revenue even if one of its products is delayed or meets regulatory issues. In addition, Inovio is also growing its cash flow, which should help it to continue to fund its operations and research and development efforts.ConclusionInvesting in the stock market is a great way to build wealth over time while also providing a way to diversify your assets and protect them against economic downturns or unexpected life events like unemployment or disability. And don’t be intimidated by the idea of investing in stocks. It’s easier than you think. All you need is a good list of the best stocks to buy now and a solid plan for investing in them.